Actavis builds antibiotic presence with $675m+ Durata deal
This article was originally published in Scrip
Executive Summary
Antibiotic developer Durata Therapeutics saw its share price rocket by up to 75% after Actavis announced a deal to acquire the Nasdaq-listed firm. Its shares rose from Friday's close of $13.88 to upwards of $24.30 during trading on Monday.
You may also be interested in...
AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed
Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.
Iterum Therapeutics Focused On First Oral Penem
Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.